My key takeaways and announcements to look out for in...

My key takeaways and announcements to look out for in short/medium term were:

• We are now gearing up for Stage 2 of the trials which will include stroke patients and patients with stroke mimics. Our regulatory engagement will be reinitiated in the coming months and we will prepare a presubmission to the FDA.
• As we grow we may choose to outsource manufacturing of our potentially high margin consumable liquid and single use disposable cap in the local geographies where sales are primarily focused.
• We have already been speaking to multiple suppliers of our subassemblies and components about volume pricing and feel that we are in a good space for the COGS (Cost of Goods Sold),continuity of supply and risk management.
• Concurrently with out Gen 1 development (typo: should be our instead of out)
• With our Gen 1device now under clinical investigation, product development and engineering resources in Sydney, alongside our Brisbane colleagues at the Translation Research Institute, have been freed up to expediate the development of our Gen 2 product.
• Inhuman testing with the prototype system is slated for later this year with road/air ambulance trials targeted for next year.
• We will continue to pursue both domestic and international non-dilutive funding pathways, including US federal agencies and private foundations, that may be available to us.
• We continue to have discussions regarding direct investment as well as distributor/partnering alliances and have recently fielded a number of in bound targets with promise.